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Differential regulation of chemokines by leukemia inhibitory factor,
interleukin-6 and oncostatin M. Leukemia inhibitory factor (LIF), on-
costatin M (OsM) and interleukin-6 (IL-6) are members of a cytokine
family, which are produced by activated macrophages and glomerular
mesangial cells. These cytokines have been implicated in the pathogenesis
of glomerular inflammation, but their action on glomerular cells is
presently unclear. Therefore, we examined the effects of JL-6, OsM and
LIF on chemokine synthesis of rat mesangial cells in culture. While LIF as
well as IL-6 up-regulated monocytc chemotactic protein-i (MCP-1)
mRNA expression, OsM showed no such effect. The induction of MCP-1
mRNA by LIF and IL-6 was transient, peaking at one to two hours and
two to three hours, respectively, and returning to background levels within
several hours. Induction of MCP-i mRNA by LIF and IL-6 was strongly
inhibited by dexamethasone. LIF activated STAT factors in mesangial
cells, suggesting their involvement in signal transduction pathways that
lead to LIF-stimulated up-regulation of MCP-i mRNA. By contrast, LIF,
IL-6 and OsM failed to affect the expression of the chemokines, macro-
phage inflammatory protein-2 (MIP-2) and RANTES. The rapid, tran-
sient and differential regulation of MCP-i expression induced by LIF and
IL-6 contrasted with uniformly powerful effects of the proinflammatory
cytokines IL-113 and TNFa that induced all tested chemokines for
prolonged time periods. These results suggest that the selective and
transient induction of MCP-l by LIF and IL-6 may play a role in the
preferential attraction of monocytes to the injured glomerulus.
Monocyte chemotactic protein-i (MCP-1), RANTES and mac-
rophage inflammatory protein-2 (MIP-2) belong to a group of low
molecular weight proteins, which induce chemotaxis and activa-
tion of a variety of inflammatory cells. These substances, called
chemokines, can attract monocytes/macrophages, lymphocytes
(MCP-1 and RANTES) and neutrophils (MIP-2) to sites of injury
and inflammation. They are expressed by many cell types found to
be involved in inflammatory processes, such as monocytes/macro-
phages and T-cells, or resident tissue cells including fibroblasts,
vascular smooth muscle cells, endothelial cells and chondrocytes
[reviewed in 1]. In the kidney, glomerular mesangial cells (MCs)
are a source for MCP-1, RANTES and MIP-2 (see below).
Chemokines have been reported to he involved in a wide range of
diseases, including hypercholesterolemia-induced atherosclerosis,
hypersensitivity reactions, autoimmune encephalomyelitis, rheu-
matoid arthritis and pulmonary fibrosis and granulomatosis [2]. In
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the diseased kidney, chemokines are also assumed to play a
pathogenetic role [3], such as in transplant rejection [4], chronic
renal failure [5], glomerulonephritis [6] and experimental tubulo-
interstitial nephritis in rats [7]. Rovin et al [8] showed that
glomerular MCP-1 was transiently up-regulated during the early
stages of a rodent model of anti-glomerular basement membrane
glomerulonephritis as well as in human inflammatory glomeru-
lopathies. Chemokines are induced in cultured MCs by proinflam-
matory cytokines. Interleukin-1/3 (IL-lp), tumor necrosis factor a
(TNFa), platelet-derived growth factor (PDGF) and interferon y
(IFNy) have been described to stimulate MCP-1 expression [9,
10]; IL-1/3 induces MIP-2 [11] and TNFa, and LPS and IL-J/3
induce RANTES in mouse and rat MCs [9]. There is as yet limited
information about chemokine induction by IL-6 and the IL-6-
related cytokines leukemia inhibitory factor (LIF) and oncostatin
M (OsM). LIF was reported to up-regulate MCP-1 in chondro-
cytes, whereas IL-6 had no detectable effect on MCP-1 mRNA
expression in these cells [12] or in human endothelial cells [13].
We have previously shown that LIF is synthesized and released by
MCs [14] and is able to exert an autocrine response in these cells,
similar to the one known for IL-6. More recently, Tang et al
confirmed that IL-1J3 induces LIF mRNA in rat MCs [15]. These
authors also showed transient up-regulation of LIF mRNA ex-
pression in glomeruli from rats 3 to 24 hours after i.v. injection of
anti-glomerular basement membrane antibody [15]. To gain fur-
ther insight in the regulation of chemokine production in MCs, we
investigated the influence of LIF, IL-6 and OsM on the mesangial
cell expression of the chemokines, MCP-1, RANTES and MIP-2.
Methods
Materials
Human recombinant IL-6 and human recombinant LIF were
from Boehringer (Mannheim, Germany). In addition, the super.
natant of transfected Chinese hamster ovary (CHO) cells was
used as a source of LIF. These cells are transfected with human
recombinant LIF, provided by Genetics Institute (Cambridge,
MA, USA). The concentration of LIF in this supernatant was
approximately 2 .rg/ml LIF protein as determined with a commer-
cially available ELISA (R&D Systems, Minneapolis, MN, USA),
corresponding to 500 U/j.d determined with the FAO/HB3 assay.
For stimulation of mesangial cells (MCs), LIF was used at a final
concentration of approximately 2 ng/ml. TNFcs with a specific
activity of 8 x 10° U/mg was kindly provided by BASF/Knoil
(Ludwigshafen, Germany), recombinant human IL-ip with a
specific activity of 2 X io U/.tg was kindly provided by Dr. J.M.
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Fig. 1. Concentration-dependence of MCP-1 mRNA induction by LIF and IL-6 in MCs. Serum-starved rat MCs were incubated for two hours with LIF
(1000 U/mI) or with PBS/O.1% BSA as a negative control (A) and for two hours with LIF or IL-6 in the concentrations indicated (B). After cell
harvesting, RNA was prepared and Northern blot analysis was performed with a rat MCP-1 eDNA probe. Hybridization with GAPDH confirmed equal
loading of both gels. The results shown are representative for 2 independent experiments.
Dayer (Geneva, Switzerland). Retinoic acid was from Sigma
(Deisenhofen, Germany).
Cell culture
Rat MCs were isolated and cultured as described [161. MCs
showed the typical vascular smooth muscle cell-like morphology
and positive immunocytochemical staining for Thy 1.1, smooth
muscle cell a-actin and myosin. MCs were grown in Dulbecco's
Modified Eagle Medium (Gibco-BRL, Eggenstein, Germany)
containing 10% FCS (Gibco), 5 .tg/ml insulin, 100 U/mI penicillin,
100 j.rg/ml streptomycin and 2 msi L-glutamine (Sigma) in a 95%
air—5% CO2 humidified atmosphere at 37°C. MCs were used for
experiments in passages 7 to 15. Before stimulation, subconfluent
cultures were serum-deprived for four days with DMEM contain-
ing 0.5% fetal calf serum (FCS), which served to synchronize the
majority of MCs in a resting state.
Isolation of RNA and Northern blot analysis
Cellular RNA was isolated by the guanidinium isothiocyanate
method as described [17]. Twenty micrograms of RNA were
loaded on a 1% agarose/1.8% formaldehyde gel, size fractionated
and transferred to a nylon membrane (Hybond N; Amersham,
Braunschweig, Germany) with 20 >< SSC overnight. Ethidium
bromide staining of the gel and membrane confirmed equal
loading and sufficient blotting of the RNA. The RNA was fixed by
baking for two hours at 80°C. The blots were probed with a 700 bp
rat MCP-1 eDNA fragment and 1021 bp rat MIP-2 eDNA
fragment (both obtained from Dr. Yoshimura, Frederick, MD,
USA), or with a 600 bp mouse RANTES eDNA fragment
(obtained from Dr. Wolf, Hamburg, Germany) respectively.
GAPDH hybridization control was carried out with a 500 bp
reverse transcribed fragment, amplified from rat mRNA using the
following PCR primers: sense primer 5'-AATGCATCCTGCAC-
CACCAA, antisense primer 5 '-GTCAlTGAGAGCAATGC-
CAGC. DNA fragments were labeled with 32P-dCTP using a
random priming kit (Amersham, Braunschweig, Germany). Pre-
hybridization was performed at 42°C for two hours with a buffer
containing 5 X SSC, 3 M NaC1, 0.3 M Na-citrate, 0.1% SDS, 5 X
Denhardt's solution, 50 mi Na2HPO4 (pH 6.5), 50% deionized
formamide and 250 sg/ml denatured salmon sperm DNA. Hy-
bridization was carried out under the same conditions for 12 to 24
hours. The membranes were washed twice with 2 >< SSC/0.1%
SDS at 40°C for 15 minutes and twice with 0.2 x SSC/0.1% SDS
for 30 minutes at the same temperature. Blots were then exposed
to a Kodak x-ray film with intensifying screen for varying time
periods. Quantitative analysis was performed by densitometric
scanning of the autoradiographs (Bioprofil, FrObel, Germany).
mRNA signals were corrected for GAPDH mRNA expression to
confirm equal loading of RNA.
Nuclear protein extracts and gel mobility shift assays
Extraction of nuclear protein and gel shift assays were per-
formed as described by Hocke, Cui and Fey [18]. Oligonucleotide
probe TB1 contains one protein-binding sequence of the LIF-
responsive element of the promoter of the a2-macroglobulin gene.
TB2 contains two of the protein-binding sequences. mTB1 con-
tains a protein-binding sequence that was inactivated by mutation.
Binding reactions were carried out for 20 minutes at room
temperature in 10 mM Hepes, pH 7.6, 50 mM KC1, 0.1 mvi EDTA,
1 mM DTT, 6 mrvi MgCl2, 2 U Trasylol (Bayer), 10 j.rg poly(dI:dC),
2 jg single stranded salmon sperm DNA, 10% glycerol, 20 rg
protein extract and approximately 100,000 cpm of double
stranded DNA probe. The double-stranded DNA probes were
end labeled with 32P y-ATP using T4 polynucleotide kinase.
Antibodies to STAT factors were from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). For mobility shift assays, 1 jig of
antibodies was added to the binding reactions and incubated at
0°C for one hour before addition of the labeled probe. The gel
shift experiment was performed using a 5% polyacrylamide gel for
separation of the probes. Gels were dried and exposed to an X-ray
film.
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Fig. 2. Time-dependence of MCP-1 mRNA
induction by LIF (A) and IL-6 (B) or IL-i /3 (C)
in MCs. Growth-arrested rat MCs were treated
with 200 U/mi L-6, 500 U/mI LIF and 5 ng/ml
A I A IL-1f3 for the times indicated. Northern blotI-rL1n — .
anaiysis was performed with probes for MCP-1
and GAPDH. The blots shown are
representative for 3 similar experiments.
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Fig. 3. Influence of OsM on MCP-l mRNA expression. Serum-starved rat
MCs were treated with 20 ng/ml OsM for the times indicated. Controls are
RNAs from cells stimulated with 5 ng/ml IL-113, 500 U/mI LIF and
PBS/0.1% BSA for two hours. Northern blot analysis was performed with
probes for MCP-1 and GAPDH. The results presented are representative
for 3 independent experiments.
Results
MCP-1 induction by LIF, IL-6 and OsM
Rat MCs were serum-starved when near confluent. Incubation
with LIF and IL-6 for two hours increased steady-state mRNA
levels for MCP-1 depending on cytokine concentration (LIF from
20 to 1000 U and IL-6 from 2 to 200 U; Fig. 1). The induction of
MCP-1 mRNA expression in rat MCs by LIF (500 U) and IL-6
(100 U) was transient (Fig. 2 A, B). Upon stimulation with LIF,
MCP-1 mRNA was markedly up-regulated after one hour and
declined after three hours. A weak background signal was visible
in unstimulated MCs and at prolonged incubation times of 15 to
20 hours. Kinetics of IL-6-induced MCP-1 expression were slightly
delayed: IL-6 did not induce MCP-1 mRNA expression prior to
two hours and MCP-1 was reduced to background level after five
to eight hours. The very strong induction of MCP-1 by IL-1f3
peaked at at three to eight hours (Fig. 2C). The expression
remained elevated for several hours. Even after 20 hours, induc-
tion was more than 15-fold.
Unlike seen for IL-6 and LIF, there was no significant induction
of MCP-1 mRNA in response to OsM over a time period of one
to eight hours (Fig. 3) at a range from 2 ng/ml to 200 ng/ml (data
not shown). Preincubation of MCs with 50 ng/ml OsM for 45
minutes and subsequent stimulation with 500 U/mi LIF for 1.5
hours showed a markedly diminished induction of MCP-1 com-
pared to the signal that was induced by LIF alone. However, OsM
applied simultaneously with LIF did not alter MCP-1 expression,
as shown in Figure 4.
In order to investigate the involvement of STAT factors in the
LIF signal transduction pathway of MCs, we performed gel
mobility shift experiments with protein isolated from nuclei of
MCs. There was a basal binding activity of STAT factors even in
uninduced cells (Fig. 5, lane 1). Treatment of MCs with LIF for
two hours led to a marked enhancement of STAT complexing
with oligonucleotide TB2 (lane 2). TB2 contained the LIF-
responsive element identified in the promoter of the rat cs2-
macroglobulin gene in two copies. TB1, an oligonucleotide with
one LIF-responsive binding site, and mutated TBI, mTBI, were
used as specificity controls. Addition of unlabeled TB1 to the
binding reaction of nuclear proteins with labeled TB2 led to a
competitive binding of nuclear STAT factors to TB1 and a
concomitant loss of the shifted TB2/protein complex. mTB1 did
Fig. 4. Effects of OsM on LIF-induced MCP-1 mRNA expression. Serum-
starved MCs were incubated simultaneously with 50 ng/ml OsM and 500
U/ml LIF for 1.5 hours, or pretreated with OsM for 45 minutes and then
stimulated with LIF for 1.5 hours. Control lanes: MCs incubated with LIF
alone or PBS/0.1% BSA for 1.5 hours. Northern blot analysis was
performed with probes for MCP-1 and GAPDH. Blots presented are
representative for two similar experiments.
not compete for STAT binding (lanes 3 and 4). Supershift
experiments with antibodies to STAT factors 1, 3 and 5 revealed
that the prominent STAT factor involved in the binding complex
is STAT 3. As shown in Figure 5 (lanes 6, 7 and 8), addition of
anti-STAT 3 caused a shift to a complex of slower mobility (S).
The glucocorticoid dexamethasone (10—v M) almost completely
inhibited MCP-1 mRNA expression after LIF induction and
markedly reduced IL-1f3-induced MCP-1 mRNA signal on the
Northern blot (Fig. 6). Retinoic acid (10-6 M), another agent
described to alter MCP-1 mRNA expression in other cell systems,
showed no such effect in MCs. Costimulation of retinoic acid with
LIF led to an MOP-i mRNA signal comparable to the one
induced by LIF alone (data not shown).
Effects of LIF, IL-6 and OsM on MIP-2 and RANTES expression
We also investigated the influence of LIF, OsM and IL-6 on the
mRNA expression of the chemokines MIP-2 and RANTES. IL-113
and TNFcs were used as positive control stimuli. After stimulation
of rat MCs with IL-1f3 (5 ng/ml), a strong MIP-2 mRNA signal
was detected, which was clearly visible after three hours and had
its maximum at 15 hours (Fig. 7). After 30 hours, the IL-1f3-
induced MIP-2 signal declined. Incubation of MCs with LIF or
IL-6 did not lead to a detectable MIP-2 signal (Fig. 7). To test
expression of RANTES mRNA, MCs were stimulated with IL-ip
(5 ng/ml) and TNFa (100 ng/ml) as a positive control. IL-lp alone
only weakly up-regulated RANTES mRNA compared to the
stronger signal in response to TNFa. In combination with TNF,
IL-113 acted synergistically showing maximal RANTES mRNA
induction at 15 to 20 hours. Neither LIF nor IL-6 were able to
induce RANTES mRNA during a time period from I to 30 hours
after stimulation, and they did not modulate the effect of TNFa
(Fig. 8). Oncostatin M had no influence on the expression of
RANTES or MIP-2 over a time period of 1 to 25 hours (data not
shown).
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Fig. 5. Activation of STATfactors by LIF. Extracts of MC nuclear protein
were prepared after two hours of MC incubation with 500 U/mI LIF and
used in a gel shift experiment with the oligonucleotide TB2 as described in
the Methods section. Control: Nuclear extracts of uninduced serum-
starved MCs were applied. There was basal activity of STAT factors, for
the gel shift revealed complex formation in untreated cells. Abbreviations
are: LIF-induced, complex formed by nuclear extracts of cells stimulated
with LIF; mTB1, addition of unlabeled mutated TB1 to the binding
reaction of LIF-induced nuclear protein and TB2; TB1, addition of
unlabeled TBI to the binding reaction of LIF-induced nuclear protein and
TB2; oSI, aS3, and aSS, nuclear extracts were incubated with antibodies
to STAT factors 1, 3 and 5, respectively, one hour prior to the addition of
TB2; A, well; S, supershifted complex. These results were obtained in two
independent experiments.
Discussion
The proinflammatory mediators 1L-13 and TNFa as well as
LPS have been shown to induce the chemokines MIP-2, MCP-1
and RANTES with comparable kinetics in various cell types [ii,
19, 201. In contrast, our findings in cultured rat MCs indicate that
LIF and IL-6 can differentially regulate these chemotactic pep-
tides. MCP-1 mRNA expression was clearly induced by LIF and
IL-6 while MIP-2 and RANTES mRNA were unaffected.
In cartilage, LIF is able to induce MCP-1 [12], whereas in
endothelial cells IL-6 does not enhance MCP-1 expression [13].
Thus, induction of chemokine expression by IL-6-like cytokines is
cell-specific, indicating that there arc selective ways for injured
xwa(I) +a::1.
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Fig. 6. Dexamethasone-mediated inhibition of MCP-I mRNA induction by
LIF and IL-1. Serum-starved MCs were incubated with 500 U/mI LIF
and 5 ng/ml IL-13 alone or in combination with dexamethasone (iO- M).
Cells were harvested after two hours and RNA was isolated. Northern blot
analysis was performed for MCP-1 and GAPDH. Results shown are
representative for five independent experiments.
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Fig. 7. Influence of JL-1j3, LIF and IL-6 on MIP-2 mRNA expression in
MCs. Growth-arrested rat MCs were treated with 5 ng/ml IL-1 for five
hours and 15 hours, with 500 U/mI LIF for 15 hours and with 200 U/mI
IL-6 for 15 hours. Control lane: cells incubated with PBS/0.l% BSA for 15
hours. Northern blot analysis was performed with probes for MIP-2 and
GAPDH. These blots are representative for three independent experi-
ments.
cells and tissues to recruit bone marrow-derived cells to the site of
inflammation.
Furthermore, IL-113 exerts its action on MCP-l induction over
an extended time period (at least 20 hr). By contrast, the actions
of LIF and IL-6 are short-lived. After one hour, MCP-1 mRNA
expression has reached its maximum and after five hours, the
MCP-1 mRNA level is reduced to the control value. LIF and IL-6
may thus serve as fast-acting regulators of chemokine induction in
MCs.
As described for many cytokines, we found that glucocorticoids
interfered with MCP-1 mRNA expression by completeJy inhibit-
ing induction. The dexamethasone-mediated down-regulation of
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MCP-1 seems to be cell-specific. In chondrocytes, vascular smooth
muscle cells and fibroblasts, MCP-1 mRNA expression was im-
paired by glucocorticoids whereas it had no effect on MCP-1
mRNA expression of endothelial cells [21]. In vascular smooth
muscle cells [211, the effect of glucocorticoids was largely due to
message destabilization, substantiating the importance of MCP-1
mRNA stability for gene expression. Thus, the inhibition of
MCP-1 mRNA expression in MCs by glucocorticoids adds to the
anti-inflammatosy properties of these compounds. Retinoic acid
was previously described as a potent stimulus for MCP-1 expres-
sion in chondrocytes [12]. In MCs, however, retinoic acid showed
no significant induction of MCP-1. Incubation of MCs with
retinoic acid in combination with LIF did not alter MCP-l mRNA
expression caused by LIF alone, whereas retinoic acid has been
shown to inhibit TNFa-indueed MCP-1 gene expression in an
osteoblastic cell line [21, 22]. Again, cell-specificity of MCP-1
mRNA regulation becomes apparent.
LIF, IL-6 and OsM belong to a group of pleiotropie cytokines
that have common transduction pathway elements like gp130,
activated Jak-kinases and STAT-factors [23]. Therefore, they
often share functional properties, for example, the ability to
induce differentiation of the murine monocytic leukemia cell line
Ml [24], or to up-regulate acute phase protein production in
hepatocytes [25]. Thus, the corresponding properties of LIF and
IL-6 with regard to chemokine regulation, found in our study, are
not unexpected. In contrast, OsM failed to induce MCP-1 mRNA
at various incubation times and concentrations. However, OsM
preincubation was able to inhibit LIF induction of MCP-1 mRNA
in MCs. OsM can act upon various cell types not only via a specific
OsM receptor but can also use the LIF receptor [26]. Our data are
compatible with the interpretation that in MCs, OsM binds to the
LIF receptor, thus preventing the binding of LIF to its receptor,
which results in reduced MCP-1 mRNA expression. Interaction of
OsM with the LIF receptor does not necessarily initiate signal
transduction leading to MCP-1 up-regulation in MCs. Our data
demonstrate that the action of LIF on MCs involves signal
transduction via Jak kinases and STAT factors. In embryonic stem
cells, STAT 3 was the major STAT factor involved in LIF-
mediated signal transduction while STAT I showed only a rela-
tively small supershift [18]. Similarly, in MCs STAT 3 seemed to
be the prominent STAT factor used for LIF-stimulated signalling.
As the MCP-1 promoter contains a consensus sequence for STAT
binding [27], STAT 3 may be essential for LIF-induced activation
of MCP-1 mRNA expression.
LIF as well as IL-6 can increase MCP-1 mRNA levels in MCs
without significantly changing the expression of other chemokines.
Therefore, LIF and IL-6 could be useful to selectively attract
monocytes-macrophages or lymphocytes to diseased tissue, with-
out increasing neutrophil infiltration. It has been shown that
MCP-1 and RANTES are expressed at different stages during
inflammatory renal diseases [3]. In the anti-Thy 1.1 model of
proliferative glomerulonephritis in the rat, MCP-1 expression was
significantly increased 30 minutes after binding of immune glob-
ulins to the mesangium [281. Since LIF and IL-6 rapidly induce
MCP-1 mRNA expression in MCs, they may be responsible for
this increase. Chemotactic peptides are differentially activated in
distinct patterns in a variety of diseases. It is unlikely that powerful
inflammatory cytokines, such as IL-1/3 or TNFa, can account for
this prompt regulation, since they up-regulate most chemokines in
parallel. IL-6 and LIF, however, could provide MCs with a means
to sensitively and quickly regulate expression of selected chemo-
kines.
It is presently unclear whether these effects of LIF and IL-6 on
MC chemokines play a beneficial or detrimental role in in vivo
processes of glomerular inflammation. Both cytokines have been
found to be expressed in various types of glomerular disease in
man [291 (Hartner et al, unpublished observations) and experi-
mental animals [15]. Autocrine effects of LIF have been observed
in cultured MCs and may contribute to early recruitment of
monocytes-macrophages [14]. Very high doses of exogenous LIF
have been described to ameliorate experimental glomerulonephri-
tis in rats [15]. The mechanism of this phenomenon is presently
uncertain. Clearly, more information is required to unravel regu-
lation and function of the glomerular cytokine network.
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